1
|
Pyka P, Garbo S, Fioravanti R, Jacob C, Hittinger M, Handzlik J, Zwergel C, Battistelli C. Selenium-containing compounds: a new hope for innovative treatments in Alzheimer's disease and Parkinson's disease. Drug Discov Today 2024; 29:104062. [PMID: 38871111 DOI: 10.1016/j.drudis.2024.104062] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2024] [Revised: 05/22/2024] [Accepted: 06/06/2024] [Indexed: 06/15/2024]
Abstract
Neurodegenerative diseases are challenging to cure. To date, no cure has been found for Alzheimer's disease or Parkinson's disease, and current treatments are able only to slow the progression of the diseases and manage their symptoms. After an introduction to the complex biology of these diseases, we discuss the beneficial effect of selenium-containing agents, which show neuroprotective effects in vitro or in vivo. Indeed, selenium is an essential trace element that is being incorporated into innovative organoselenium compounds, which can improve outcomes in rodent or even primate models with neurological deficits. Herein, we critically discuss recent findings in the field of selenium-based applications in neurological disorders.
Collapse
Affiliation(s)
- Patryk Pyka
- Department of Technology and Biotechnology of Drugs, Jagiellonian University, Medical College, Medyczna 9, 30-688 Krakow, Poland; Doctoral School of Medical and Health Sciences, Jagiellonian University Medical College, św. Łazarza 15, 31-530 Krakow, Poland; Istituto Pasteur Italia, Fondazione Cenci-Bolognetti, Department of Molecular Medicine, Sapienza University of Rome, Viale Regina Elena 324, 00161, Rome, Italy
| | - Sabrina Garbo
- Istituto Pasteur Italia, Fondazione Cenci-Bolognetti, Department of Molecular Medicine, Sapienza University of Rome, Viale Regina Elena 324, 00161, Rome, Italy
| | - Rossella Fioravanti
- Department of Drug Chemistry and Technologies, Sapienza University of Rome, Piazzale Aldo Moro 5, 00185 Rome, Italy
| | - Claus Jacob
- Division of Bioorganic Chemistry, School of Pharmacy, Saarland University, Campus B 2.1, D-66123 Saarbrücken, Germany
| | - Marius Hittinger
- Pharmbiotec gGmbH, Department of Drug Discovery, Nußkopf 39, 66578 Schiffweiler, Germany
| | - Jadwiga Handzlik
- Department of Technology and Biotechnology of Drugs, Jagiellonian University, Medical College, Medyczna 9, 30-688 Krakow, Poland.
| | - Clemens Zwergel
- Department of Drug Chemistry and Technologies, Sapienza University of Rome, Piazzale Aldo Moro 5, 00185 Rome, Italy; Division of Bioorganic Chemistry, School of Pharmacy, Saarland University, Campus B 2.1, D-66123 Saarbrücken, Germany; Pharmbiotec gGmbH, Department of Drug Discovery, Nußkopf 39, 66578 Schiffweiler, Germany.
| | - Cecilia Battistelli
- Istituto Pasteur Italia, Fondazione Cenci-Bolognetti, Department of Molecular Medicine, Sapienza University of Rome, Viale Regina Elena 324, 00161, Rome, Italy.
| |
Collapse
|
2
|
Salaramoli S, Joshaghani HR, Hosseini M, Hashemy SI. Therapeutic Effects of Selenium on Alpha-Synuclein Accumulation in Substantia Nigra Pars Compacta in a Rat Model of Parkinson's Disease: Behavioral and Biochemical Outcomes. Biol Trace Elem Res 2024; 202:1115-1125. [PMID: 37386228 DOI: 10.1007/s12011-023-03748-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/09/2022] [Accepted: 06/24/2023] [Indexed: 07/01/2023]
Abstract
Parkinson's disease (PD) is the second most common progressive neurodegenerative disorder characterized by the accumulation of accumulated alpha-synuclein (α-Syn) in substantia nigra. Research has shown that selenium (Se) can protect neural cells through the actions of selenoproteins, including selenoprotein P (SelP) and selenoprotein S (SelS), which participate in endoplasmic reticulum-associated protein degradation (ERAD). In this study, we investigated the potential protective role of Se in a pre-clinical PD rat model.We aimed to evaluate the therapeutic effects of Se administration in the 6-hydroxydopamine (6-OHDA) induced unilateral rat PD model. Male Wistar rats were utilised for unilateral PD animal model which were subjected to stereotaxic surgery and injected with 20 μg 6-OHDA/5 μl 0.2% ascorbate saline. After confirming the model, the rats were intraperitoneally injected with 0.1, 0.2, and 0.3 mg/kg of sodium selenite for 7 days. We then performed behavioral tests, including apomorphine-induced rotation, hanging, and rotarod tests. Following sacrifice, we analysed the substantia nigra area of the brain and serum for protein quantification, element analysis, and gene expression analysis.Our results indicate that the administration of 0.3 mg/kg of Se improved the motor deficiency in hanging, rotarod, and apomorphine-induced rotational tests. While there was no significant improvement in the expression of α-Syn, Se increased the expression of selenoproteins. Additionally, levels of selenoproteins, Se, and α-Syn both brain and serum were re-established by the treatment, suggesting the role of Se on the α-Syn accumulation. Furthermore, Se improved PD-induced biochemical deficits by increasing the levels of SelS and SelP (p<0.005).In conclusion, our findings suggest that Se may have a protective role in PD. 0.3 mg/kg dosage of Se increased the expression of selenoproteins, reduced the accumulation of α-Syn in the brain, and improved PD-induced motor deficits. These results suggest that Se may be a potential therapeutic option for PD treatment.
Collapse
Affiliation(s)
- Sanaz Salaramoli
- Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
- Department of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
| | - Hamid Reza Joshaghani
- Laboratory Sciences Research Centre, Golestan University of Medical Sciences, Gorgan, Iran
| | - Mahmoud Hosseini
- Division of Neurocognitive Sciences, Psychiatry and Behavioural Sciences Research Centre, Mashhad University of Medical Sciences, Mashhad, Iran
| | - Seyed Isaac Hashemy
- Department of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
- Surgical Oncology Research Centre, Mashhad University of Medical Sciences, Mashhad, Iran.
| |
Collapse
|
3
|
Xu K, Huang P, Wu Y, Liu T, Shao N, Zhao L, Hu X, Chang J, Peng Y, Qu S. Engineered Selenium/Human Serum Albumin Nanoparticles for Efficient Targeted Treatment of Parkinson's Disease via Oral Gavage. ACS NANO 2023; 17:19961-19980. [PMID: 37807265 PMCID: PMC10604087 DOI: 10.1021/acsnano.3c05011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/04/2023] [Accepted: 10/04/2023] [Indexed: 10/10/2023]
Abstract
Parkinson's disease (PD) is a neurodegenerative disorder characterized by the degeneration of dopamine (DA) neurons in the midbrain substantia nigra pars compacta (SNpc). While existing therapeutic strategies can alleviate PD symptoms, they cannot inhibit DA neuron loss. Herein, a tailor-made human serum albumin (HSA)-based selenium nanosystem (HSA/Se nanoparticles, HSA/Se NPs) to treat PD that can overcome the intestinal epithelial barrier (IEB) and blood-brain barrier (BBB) is described. HSA, a transporter for drug delivery, has superior biological characteristics that make it an ideal potential drug delivery substance. Findings reveal that HSA/Se NPs have lower toxicity and higher efficacy than other selenium species and the ability to overcome the IEB and BBB to enrich DA neurons, which then protect MN9D cells from MPP+-induced neurotoxicity and ameliorate both behavioral deficits and DA neuronal death in MPTP-model mice. Thus, a therapeutic drug delivery system composed of orally gavaged HSA/Se NPs for the treatment of PD is described.
Collapse
Affiliation(s)
- Kai Xu
- Department
of Neurology, Nanfang Hospital, Southern
Medical University, Guangzhou, Guangdong 510515, China
- Guangdong-Hong
Kong-Macao Greater Bay Area Center for Brain Science and Brain-Inspired
Intelligence, Guangzhou, Guangdong 510515, China
- Key
Laboratory of Mental Health of the Ministry of Education, Southern Medical University, Guangzhou, Guangdong 510515, China
| | - Peng Huang
- Department
of Neurology, Nanfang Hospital, Southern
Medical University, Guangzhou, Guangdong 510515, China
- Guangdong-Hong
Kong-Macao Greater Bay Area Center for Brain Science and Brain-Inspired
Intelligence, Guangzhou, Guangdong 510515, China
- Key
Laboratory of Mental Health of the Ministry of Education, Southern Medical University, Guangzhou, Guangdong 510515, China
| | - Yixuan Wu
- Department
of Neurology, Nanfang Hospital, Southern
Medical University, Guangzhou, Guangdong 510515, China
- Guangdong-Hong
Kong-Macao Greater Bay Area Center for Brain Science and Brain-Inspired
Intelligence, Guangzhou, Guangdong 510515, China
- Key
Laboratory of Mental Health of the Ministry of Education, Southern Medical University, Guangzhou, Guangdong 510515, China
| | - Teng Liu
- Department
of Neonatology and Pediatrics, Xiangya Hospital
of Central South University, Changsha, Hunan 410008, China
| | - Ningyi Shao
- Cancer
Centre, Faculty of Health Sciences, University
of Macau, Taipa, Macau Special Administrative Region 999078, China
| | - Lulu Zhao
- Chongqing
Key Laboratory for Pharmaceutical Metabolism Research, The Key Laboratory
of Biochemistry and Molecular Pharmacology, College of Pharmacy, Chongqing Medical University, Chongqing 400016, China
| | - Xiaoyan Hu
- Shenzhen
Key Laboratory of Biomimetic Materials and Cellular Immunomodulation,
Institute of Biomedicine and Biotechnology, Shenzhen Institute of
Advanced Technology, Chinese Academy of
Sciences, Shenzhen, Guangdong 518055, China
- University
of Chinese Academy of Sciences, Beijing 100864, China
| | - Junlei Chang
- Shenzhen
Key Laboratory of Biomimetic Materials and Cellular Immunomodulation,
Institute of Biomedicine and Biotechnology, Shenzhen Institute of
Advanced Technology, Chinese Academy of
Sciences, Shenzhen, Guangdong 518055, China
| | - Yongbo Peng
- Chongqing
Key Laboratory for Pharmaceutical Metabolism Research, The Key Laboratory
of Biochemistry and Molecular Pharmacology, College of Pharmacy, Chongqing Medical University, Chongqing 400016, China
| | - Shaogang Qu
- Department
of Neurology, Nanfang Hospital, Southern
Medical University, Guangzhou, Guangdong 510515, China
- Guangdong-Hong
Kong-Macao Greater Bay Area Center for Brain Science and Brain-Inspired
Intelligence, Guangzhou, Guangdong 510515, China
- Key
Laboratory of Mental Health of the Ministry of Education, Southern Medical University, Guangzhou, Guangdong 510515, China
- Department
of Neurology, Ganzhou People’s Hospital, Ganzhou, Jiangxi 341000, China
| |
Collapse
|
4
|
Alvi S, Jayant V, Ali R. Applications of Oxone® in Organic Synthesis: An Emerging Green Reagent of Modern Era. ChemistrySelect 2022. [DOI: 10.1002/slct.202200704] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- Shakeel Alvi
- Department of Chemistry, Jamia Millia Islamia, Jamia Nagar, Okhla New Delhi 110025 India
| | - Vikrant Jayant
- Department of Chemistry, Jamia Millia Islamia, Jamia Nagar, Okhla New Delhi 110025 India
| | - Rashid Ali
- Department of Chemistry, Jamia Millia Islamia, Jamia Nagar, Okhla New Delhi 110025 India
| |
Collapse
|
5
|
Soman SK, Tingle D, Dagda RY, Torres M, Dagda M, Dagda RK. Cleaved PINK1 induces neuronal plasticity through PKA-mediated BDNF functional regulation. J Neurosci Res 2021; 99:2134-2155. [PMID: 34046942 DOI: 10.1002/jnr.24854] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/24/2020] [Revised: 04/29/2021] [Accepted: 04/30/2021] [Indexed: 12/17/2022]
Abstract
Mutations in PTEN-induced kinase 1 (PINK1) lead to early onset autosomal recessive Parkinson's disease in humans. In healthy neurons, full-length PINK1 (fPINK1) is post-translationally cleaved into different lower molecular weight forms, and cleaved PINK1 (cPINK1) gets shuttled to the cytosolic compartments to support extra-mitochondrial functions. While numerous studies have exemplified the role of mitochondrially localized PINK1 in modulating mitophagy in oxidatively stressed neurons, little is known regarding the physiological role of cPINK1 in healthy neurons. We have previously shown that cPINK1, but not fPINK1, modulates the neurite outgrowth and the maintenance of dendritic arbors by activating downstream protein kinase A (PKA) signaling in healthy neurons. However, the molecular mechanisms by which cPINK1 promotes neurite outgrowth remain to be elucidated. In this report, we show that cPINK1 supports neuronal development by modulating the expression and extracellular release of brain-derived neurotrophic factor (BDNF). Consistent with this role, we observed a progressive increase in the level of endogenous cPINK1 but not fPINK1 during prenatal and postnatal development of mouse brains and during development in primary cortical neurons. In cultured primary neurons, the pharmacological activation of endogenous PINK1 leads to enhanced downstream PKA activity, subsequent activation of the PKA-modulated transcription factor cAMP response element-binding protein (CREB), increased intracellular production and extracellular release of BDNF, and enhanced activation of the BDNF receptor-TRKβ. Mechanistically, cPINK1-mediated increased dendrite complexity requires the binding of extracellular BDNF to TRKβ. In summary, our data support a physiological role of cPINK1 in stimulating neuronal development by activating the PKA-CREB-BDNF signaling axis in a feedforward loop.
Collapse
Affiliation(s)
- Smijin K Soman
- Department of Pharmacology, University of Nevada, Reno School of Medicine, Reno, NV, USA
| | - David Tingle
- Department of Pharmacology, University of Nevada, Reno School of Medicine, Reno, NV, USA
| | - Raul Y Dagda
- Department of Pharmacology, University of Nevada, Reno School of Medicine, Reno, NV, USA
| | - Mariana Torres
- Department of Pharmacology, University of Nevada, Reno School of Medicine, Reno, NV, USA
| | - Marisela Dagda
- Department of Pharmacology, University of Nevada, Reno School of Medicine, Reno, NV, USA
| | - Ruben K Dagda
- Department of Pharmacology, University of Nevada, Reno School of Medicine, Reno, NV, USA
| |
Collapse
|
6
|
Balakrishnan R, Azam S, Cho DY, Su-Kim I, Choi DK. Natural Phytochemicals as Novel Therapeutic Strategies to Prevent and Treat Parkinson's Disease: Current Knowledge and Future Perspectives. OXIDATIVE MEDICINE AND CELLULAR LONGEVITY 2021; 2021:6680935. [PMID: 34122727 PMCID: PMC8169248 DOI: 10.1155/2021/6680935] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/16/2020] [Revised: 04/14/2021] [Accepted: 04/26/2021] [Indexed: 12/12/2022]
Abstract
Parkinson's disease (PD) is the second-most common neurodegenerative chronic disease affecting both cognitive performance and motor functions in aged people. Yet despite the prevalence of this disease, the current therapeutic options for the management of PD can only alleviate motor symptoms. Research has explored novel substances for naturally derived antioxidant phytochemicals with potential therapeutic benefits for PD patients through their neuroprotective mechanism, targeting oxidative stress, neuroinflammation, abnormal protein accumulation, mitochondrial dysfunction, endoplasmic reticulum stress, neurotrophic factor deficit, and apoptosis. The aim of the present study is to perform a comprehensive evaluation of naturally derived antioxidant phytochemicals with neuroprotective or therapeutic activities in PD, focusing on their neuropharmacological mechanisms, including modulation of antioxidant and anti-inflammatory activity, growth factor induction, neurotransmitter activity, direct regulation of mitochondrial apoptotic machinery, prevention of protein aggregation via modulation of protein folding, modification of cell signaling pathways, enhanced systemic immunity, autophagy, and proteasome activity. In addition, we provide data showing the relationship between nuclear factor E2-related factor 2 (Nrf2) and PD is supported by studies demonstrating that antiparkinsonian phytochemicals can activate the Nrf2/antioxidant response element (ARE) signaling pathway and Nrf2-dependent protein expression, preventing cellular oxidative damage and PD. Furthermore, we explore several experimental models that evaluated the potential neuroprotective efficacy of antioxidant phytochemical derivatives for their inhibitory effects on oxidative stress and neuroinflammation in the brain. Finally, we highlight recent developments in the nanodelivery of antioxidant phytochemicals and its neuroprotective application against pathological conditions associated with oxidative stress. In conclusion, naturally derived antioxidant phytochemicals can be considered as future pharmaceutical drug candidates to potentially alleviate symptoms or slow the progression of PD. However, further well-designed clinical studies are required to evaluate the protective and therapeutic benefits of phytochemicals as promising drugs in the management of PD.
Collapse
Affiliation(s)
- Rengasamy Balakrishnan
- Department of Applied Life Science, Graduate School, BK21 Program, Konkuk University, Chungju 27478, Republic of Korea
- Department of Biotechnology, College of Biomedical and Health Science, Research Institute of Inflammatory Disease (RID), Konkuk University, Chungju 27478, Republic of Korea
| | - Shofiul Azam
- Department of Applied Life Science, Graduate School, BK21 Program, Konkuk University, Chungju 27478, Republic of Korea
| | - Duk-Yeon Cho
- Department of Applied Life Science, Graduate School, BK21 Program, Konkuk University, Chungju 27478, Republic of Korea
| | - In Su-Kim
- Department of Biotechnology, College of Biomedical and Health Science, Research Institute of Inflammatory Disease (RID), Konkuk University, Chungju 27478, Republic of Korea
| | - Dong-Kug Choi
- Department of Applied Life Science, Graduate School, BK21 Program, Konkuk University, Chungju 27478, Republic of Korea
- Department of Biotechnology, College of Biomedical and Health Science, Research Institute of Inflammatory Disease (RID), Konkuk University, Chungju 27478, Republic of Korea
| |
Collapse
|
7
|
Toxicology and pharmacology of synthetic organoselenium compounds: an update. Arch Toxicol 2021; 95:1179-1226. [PMID: 33792762 PMCID: PMC8012418 DOI: 10.1007/s00204-021-03003-5] [Citation(s) in RCA: 103] [Impact Index Per Article: 34.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2021] [Accepted: 02/10/2021] [Indexed: 12/17/2022]
Abstract
Here, we addressed the pharmacology and toxicology of synthetic organoselenium compounds and some naturally occurring organoselenium amino acids. The use of selenium as a tool in organic synthesis and as a pharmacological agent goes back to the middle of the nineteenth and the beginning of the twentieth centuries. The rediscovery of ebselen and its investigation in clinical trials have motivated the search for new organoselenium molecules with pharmacological properties. Although ebselen and diselenides have some overlapping pharmacological properties, their molecular targets are not identical. However, they have similar anti-inflammatory and antioxidant activities, possibly, via activation of transcription factors, regulating the expression of antioxidant genes. In short, our knowledge about the pharmacological properties of simple organoselenium compounds is still elusive. However, contrary to our early expectations that they could imitate selenoproteins, organoselenium compounds seem to have non-specific modulatory activation of antioxidant pathways and specific inhibitory effects in some thiol-containing proteins. The thiol-oxidizing properties of organoselenium compounds are considered the molecular basis of their chronic toxicity; however, the acute use of organoselenium compounds as inhibitors of specific thiol-containing enzymes can be of therapeutic significance. In summary, the outcomes of the clinical trials of ebselen as a mimetic of lithium or as an inhibitor of SARS-CoV-2 proteases will be important to the field of organoselenium synthesis. The development of computational techniques that could predict rational modifications in the structure of organoselenium compounds to increase their specificity is required to construct a library of thiol-modifying agents with selectivity toward specific target proteins.
Collapse
|
8
|
IDO-1 inhibition protects against neuroinflammation, oxidative stress and mitochondrial dysfunction in 6-OHDA induced murine model of Parkinson's disease. Neurotoxicology 2021; 84:184-197. [PMID: 33774066 DOI: 10.1016/j.neuro.2021.03.009] [Citation(s) in RCA: 21] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2019] [Revised: 03/15/2021] [Accepted: 03/22/2021] [Indexed: 01/02/2023]
Abstract
Parkinson's disease (PD), a common neurodegenerative motor disorder characterized by striatal dopaminergic neuronal loss and localized neuroinflammation in the midbrain region. Activation of microglia is associated with various inflammatory mediators and Kynurenine pathway (KP) being one of the major regulator of immune response, is involved in the neuroinflammatory and neurotoxic cascade in PD. In the current study, 1-Methyltryptophan (1-MT), an Indolamine-2,3-dioxygenase-1 (IDO-1) inhibitor was tested at different doses (2.5 mg/kg, 5 mg/kg and 10 mg/kg) for its effect on behavioral parameters, oxidative stress, neuroinflammation, apoptosis, mitochondrial dysfunction, neurotransmitter levels, biochemical and behavioral alterations in unilateral 6-OHDA (3 μg/μL) murine model of PD. The results showed improved locomotion in open field test and motor coordination in rota-rod, reduced oxidative stress, neuroinflammatory markers (TNF-α, IFN-γ, IL-6), mitochondrial dysfunction and neuronal apoptosis (caspase-3). Also, restoration of neurotransmitter levels (dopamine and homovanillic acid) in the striatum and increased striatal BDNF levels were observed. Overall findings suggest that 1-MT could be a potential candidate for further studies to explore its possibility as an alternative in the pharmacotherapy of PD.
Collapse
|
9
|
Zhang C, Wang H, Liang W, Yang Y, Cong C, Wang Y, Wang S, Wang X, Wang D, Huo D, Feng H. Diphenyl diselenide protects motor neurons through inhibition of microglia-mediated inflammatory injury in amyotrophic lateral sclerosis. Pharmacol Res 2021; 165:105457. [PMID: 33515706 DOI: 10.1016/j.phrs.2021.105457] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/29/2020] [Revised: 01/19/2021] [Accepted: 01/22/2021] [Indexed: 12/15/2022]
Abstract
Microglia-mediated neuroinflammatory response and neuron damage are considered as a self-propelling progressive cycle, being strongly implicated in the progression of neurodegeneration in amyotrophic lateral sclerosis (ALS). Diphenyl diselenide (DPDS), a simple organoselenium compound, has been known to possess multiple pharmacological properties. The purpose of this study was to explore the neuroprotective effects of DPDS against microglia-mediated neuroinflammatory injury in ALS models. We found that DPDS pretreatment inhibited LPS-induced activation of IκB/NF-κB pathway and subsequent release of proinflammatory factors from activated primary hSOD1G93A microglia. Moreover, DPDS suppressed NLRP3 inflammasome activation by decreasing protein nitration via reduction in NO and ROS levels, whose low levels are related to NF-κB inhibition responsible for iNOS and NOX2 down-regulations, respectively. Notably, DPDS-mediated ROS attenuation was not linked to Nrf2 activation in this cellular model. Furthermore, in the absence of activated microglia, DPDS has no significant effect on the individual hSOD1G93A-NSC34 cells; however, in in vitro neuron-microglia conditional culture and co-culture experiments, DPDS protected motor neurons from neurotoxic damage caused by LPS or BzATP-stimulated microglia activation. Above observations suggest that DPDS-afforded neuroprotection is linked to inhibition of microglia-mediated neuroinflammation in ALS, which was further verified in vivo as shown by improvements of motor deficits, prolonged survival, and reduction of motor neuron loss and reactive microgliosis in hSOD1G93A transgenic mouse. Altogether, our results show that DPDS elicited neuroprotection in ALS models through inactivation of microglia by inhibiting IκB/NF-κB pathway and NLRP3 inflammasome activation, suggesting that DPDS may be a promising candidate for potential therapy for ALS.
Collapse
Affiliation(s)
- Chunting Zhang
- Department of Neurology, The First Affiliated Hospital of USTC, Division of Life Science and Medicine, University of Science and Technology of China, Hefei City, Anhui Province, PR China; Department of Neurology, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang Province, PR China
| | - Hongyong Wang
- Department of Neurology, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang Province, PR China
| | - Weiwei Liang
- Department of Neurology, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang Province, PR China; Department of Neurology, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang Province, PR China
| | - Yueqing Yang
- Department of Neurology, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang Province, PR China
| | - Chaohua Cong
- Department of Neurology, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang Province, PR China
| | - Ying Wang
- Department of Neurology, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang Province, PR China
| | - Shuyu Wang
- Department of Neurology, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang Province, PR China
| | - Xudong Wang
- Department of Neurology, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang Province, PR China
| | - Di Wang
- Department of Neurology, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang Province, PR China
| | - Di Huo
- Department of Neurology, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang Province, PR China
| | - Honglin Feng
- Department of Neurology, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang Province, PR China.
| |
Collapse
|
10
|
Galant LS, Rafique J, Braga AL, Braga FC, Saba S, Radi R, da Rocha JBT, Santi C, Monsalve M, Farina M, de Bem AF. The Thiol-Modifier Effects of Organoselenium Compounds and Their Cytoprotective Actions in Neuronal Cells. Neurochem Res 2020; 46:120-130. [PMID: 32285377 DOI: 10.1007/s11064-020-03026-x] [Citation(s) in RCA: 19] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2019] [Revised: 03/31/2020] [Accepted: 04/04/2020] [Indexed: 01/10/2023]
Abstract
Most pharmacological studies concerning the beneficial effects of organoselenium compounds have focused on their ability to mimic glutathione peroxidase (GPx). However, mechanisms other than GPx-like activity might be involved on their biological effects. This study was aimed to investigate and compare the protective effects of two well known [(PhSe)2 and PhSeZnCl] and two newly developed (MRK Picolyl and MRK Ester) organoselenium compounds against oxidative challenge in cultured neuronal HT22 cells. The thiol peroxidase and oxidase activities were performed using the glutathione reductase (GR)-coupled assay. In order to evaluate protective effects of the organoselenium compounds against oxidative challenge in neuronal HT22 cells, experiments based on glutamate-induced oxytosis and SIN-1-mediated peroxynitrite generation were performed. The thiol peroxidase activities of the studied organoselenium compounds were smaller than bovine erythrocytes GPx enzyme. Besides, (PhSe)2 and PhSeZnCl showed higher thiol peroxidase and lower thiol oxidase activities compared to the new compounds. MRK Picolyl and MRK Ester, which showed lower thiol peroxidase activity, showed higher thiol oxidase activity. Both pre- or co-treatment with (PhSe)2, PhSeZnCl, MRK Picolyl and MRK Ester protected HT22 cells against glutamate-induced cytotoxicity. (PhSe)2 and MRK Picolyl significantly prevented peroxinitrite-induced dihydrorhodamine oxidation, but this effect was observed only when HT22 were pre-treated with these compounds. The treatment with (PhSe)2 increased the protein expression of antioxidant defences (Prx3, CAT and GCLC) in HT22 cells. Taking together, our results suggest that the biological effects elicited by these compounds are not directly related to their GPx-mimetic and thiol oxidase activities, but might be linked to the up-regulation of endogenous antioxidant defences trough their thiol-modifier effects.
Collapse
Affiliation(s)
- Letícia Selinger Galant
- Biochemistry PhD Program, Department of Biochemistry, Federal University of Santa Catarina, Florianopolis, SC, Brazil
| | - Jamal Rafique
- Department of Chemistry, Center for Biological Sciences, Federal University of Santa Catarina, Florianópolis, Brazil.,Instituto de Química, Universidade Federal Do Mato Grosso Do Sul, Campo Grande, MS, 79074-460, Brazil
| | - Antônio Luiz Braga
- Department of Chemistry, Center for Biological Sciences, Federal University of Santa Catarina, Florianópolis, Brazil
| | - Felipe Camargo Braga
- Instituto de Química, Universidade Federal Do Mato Grosso Do Sul, Campo Grande, MS, 79074-460, Brazil
| | - Sumbal Saba
- Centro de Ciências Naturais E Humanas-CCNH, Universidade Federal Do ABC, Santo André, SP, 09210-580, Brazil
| | - Rafael Radi
- Center for Free Radical and Biomedical Research (CEINBIO), Facultad de Medicina, Universidad de La República, Montevideo, Uruguay
| | | | - Claudio Santi
- Department of Pharmaceutical Sciences, University of Perugia, Perugia, Italy
| | - Maria Monsalve
- Instituto de Investigaciones Biomédicas "Alberto Sols" (CSIC-UAM), Arturo Duperier 4, 28029, Madrid, Spain
| | - Marcelo Farina
- Biochemistry PhD Program, Department of Biochemistry, Federal University of Santa Catarina, Florianopolis, SC, Brazil.
| | - Andreza Fabro de Bem
- Biochemistry PhD Program, Department of Biochemistry, Federal University of Santa Catarina, Florianopolis, SC, Brazil. .,Departament of Physiological Science, Institute for Biological Sciences, University of Brasília, Brasília, Brazil.
| |
Collapse
|
11
|
Baldissera MD, Souza CF, da Silva AS, Henn AS, Flores EMM, Baldisserotto B. Diphenyl diselenide dietary supplementation alleviates behavior impairment and brain damage in grass carp (Ctenopharyngodon idella) exposed to methylmercury chloride. Comp Biochem Physiol C Toxicol Pharmacol 2020; 229:108674. [PMID: 31760078 DOI: 10.1016/j.cbpc.2019.108674] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/19/2019] [Revised: 11/14/2019] [Accepted: 11/20/2019] [Indexed: 12/11/2022]
Abstract
Mercury (Hg) induces neurobehavioral disorders through reactive oxygen species (ROS) elevation and impairment of brain key enzyme activities. Nevertheless, the therapeutic and toxic selenium concentrations for fish are very close; diphenyl diselenide (Ph2Se2), an organoselenium compound with neuroprotective effects, may be an alternative to elemental Se. Therefore, the aim of this study was to determine whether dietary supplementation with Ph2Se2 prevented or reduced the neurobehavioral alterations and oxidative damage elicited by CH3HgCl in grass carp Ctenopharyngodon idella. Fish exposed to CH3HgCl exhibited significantly reduced distance travelled and swimming speed compared to the control group, as well as augmented cortisol and ROS levels and xanthine oxidase (XO) activities. CH3HgCl exposure significantly increased lipid peroxidation (LOOH) and protein carbonylation (PC) levels compared to those of the control group, while acetylcholinesterase (AChE) and sodium-potassium pump (Na+, K+-ATPase) activities were inhibited. Dietary supplementation with 3 mg/kg Ph2Se2 ameliorated locomotor activity impairment and prevented the augmented brain cortisol and ROS levels as well as XO activity. The supplement reduced lipid and protein damage elicited by CH3HgCl and exerted protective effects on brain AChE and Na+, K+-ATPase activities. Exposure to an environmental concentration of CH3HgCl elicited neurobehavioral alterations linked to reduced locomotor activity, a finding that can be explained by oxidative damage and reduced activity of AChE and Na+, K+-ATPase in telencephalon and mesencephalon structures. Dietary supplementation with Ph2Se2 prevented CH3HgCl-induced locomotor impairment. This effect appeared to be mediated by antioxidant action. Ph2Se2 may be a viable approach to prevention or reduction CH3HgCl-mediated neurotoxic effects.
Collapse
Affiliation(s)
- Matheus D Baldissera
- Department of Physiology and Pharmacology, Universidade Federal de Santa Maria, Santa Maria, RS, Brazil.
| | - Carine F Souza
- Department of Physiology and Pharmacology, Universidade Federal de Santa Maria, Santa Maria, RS, Brazil
| | - Aleksandro S da Silva
- Department of Animal Science, Universidade do Estado de Santa Catarina, Chapecó, SC, Brazil
| | - Alessandra S Henn
- Department of Chemistry, Universidade Federal de Santa Maria (UFSM), Santa Maria, RS, Brazil
| | - Erico M M Flores
- Department of Chemistry, Universidade Federal de Santa Maria (UFSM), Santa Maria, RS, Brazil
| | - Bernardo Baldisserotto
- Department of Physiology and Pharmacology, Universidade Federal de Santa Maria, Santa Maria, RS, Brazil
| |
Collapse
|
12
|
Yamakawa GR, Eyolfson E, Weerawardhena H, Mychasiuk R. Administration of diphenyl diselenide (PhSe)2 following repetitive mild traumatic brain injury exacerbates anxiety-like symptomology in a rat model. Behav Brain Res 2020; 382:112472. [DOI: 10.1016/j.bbr.2020.112472] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2019] [Revised: 01/05/2020] [Accepted: 01/05/2020] [Indexed: 02/07/2023]
|
13
|
Neuroprotective potential of chrysin in Parkinson's disease: Molecular mechanisms and clinical implications. Neurochem Int 2020; 132:104612. [DOI: 10.1016/j.neuint.2019.104612] [Citation(s) in RCA: 41] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2019] [Revised: 11/24/2019] [Accepted: 11/25/2019] [Indexed: 01/09/2023]
|
14
|
de Freitas Couto S, Araujo SM, Bortolotto VC, Poetini MR, Pinheiro FC, Santos Musachio EA, Meichtry LB, do Sacramento M, Alves D, La Rosa Novo D, Mesko MF, Prigol M. 7-chloro-4-(phenylselanyl) quinoline prevents dopamine depletion in a Drosophila melanogaster model of Parkinson's-like disease. J Trace Elem Med Biol 2019; 54:232-243. [PMID: 30366679 DOI: 10.1016/j.jtemb.2018.10.015] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/15/2018] [Revised: 09/06/2018] [Accepted: 10/12/2018] [Indexed: 10/28/2022]
Abstract
Neurodegeneration in Parkinson's disease appears to be caused by multiple factors, including oxidative damage and an increase in acetylcholinesterase expression that can culminate in loss of dopaminergic neurons. A selenium-containing quinoline derivative, 7-chloro-4-(phenylselanyl) quinoline (4-PSQ), shows important pharmacological actions mainly attributed to its antioxidant and anticholinesterase properties. Thus, this study investigated the neuroprotective effect of 4-PSQ in a model of Parkinson's-like disease induced by rotenone (ROT) in Drosophila melanogaster and verified whether these effects are related to selenium levels. Adult flies were divided into: [1] control, [2] 4-PSQ (25 μM), [3] ROT (500 μM), and [4] 4-PSQ (25 μM) + ROT (500 μM) groups and exposed to a diet containing ROT and/or 4-PSQ for 7 days, according to their respective groups. Survival, behavioral, and ex vivo analyses were performed. Dopamine levels, reactive species levels (RS), lipid peroxidation (LPO), superoxide dismutase (SOD) and catalase (CAT) activity, and proteic thiol (PSH) and non-proteic thiol (NPSH) content in the head region were analyzed, while acetylcholinesterase (AChE) activity and selenium levels in the head and body regions were analyzed. 4-PSQ was able to reverse the ROT-induced deficits in flies, reestablish dopamine and selenium levels, reverse cholinergic deficits, improve motor function, and ameliorate mortality. Furthermore, 4-PSQ also reduced RS levels and LPO, and restored the activities of the antioxidant enzymes, SOD and CAT. Interestingly, a positive relationship between dopamine and selenium levels could be seen. Our results demonstrate the neuroprotective effect of 4-PSQ, and we suggest that the compound may act via different mechanisms, such as improving antioxidant defenses and consequently reducing oxidative damages, as well as having an anticholinesterase action, which together can prevent dopamine depletion, as these actions were correlated with the presence of selenium in the 4-PSQ molecule.
Collapse
Affiliation(s)
- Shanda de Freitas Couto
- Laboratório de Avaliações Farmacológicas e Toxicológicas Aplicadas às Moléculas Bioativas, LaftamBio Pampa, Universidade Federal do Pampa, Campus Itaqui, Rua Luiz Joaquim de Sá Britto, s/n - Bairro: Promorar, Itaqui, Rio Grande do Sul, CEP 97650-000, Brazil; Department of Nutrition, Universidade Federal do Pampa, Campus Itaqui, Rua Luiz Joaquim de Sá Britto, s/n - Bairro: Promorar, Itaqui, Rio Grande do Sul, CEP 97650-000, Brazil
| | - Stífani Machado Araujo
- Laboratório de Avaliações Farmacológicas e Toxicológicas Aplicadas às Moléculas Bioativas, LaftamBio Pampa, Universidade Federal do Pampa, Campus Itaqui, Rua Luiz Joaquim de Sá Britto, s/n - Bairro: Promorar, Itaqui, Rio Grande do Sul, CEP 97650-000, Brazil
| | - Vandreza Cardoso Bortolotto
- Laboratório de Avaliações Farmacológicas e Toxicológicas Aplicadas às Moléculas Bioativas, LaftamBio Pampa, Universidade Federal do Pampa, Campus Itaqui, Rua Luiz Joaquim de Sá Britto, s/n - Bairro: Promorar, Itaqui, Rio Grande do Sul, CEP 97650-000, Brazil
| | - Marcia Rósula Poetini
- Laboratório de Avaliações Farmacológicas e Toxicológicas Aplicadas às Moléculas Bioativas, LaftamBio Pampa, Universidade Federal do Pampa, Campus Itaqui, Rua Luiz Joaquim de Sá Britto, s/n - Bairro: Promorar, Itaqui, Rio Grande do Sul, CEP 97650-000, Brazil
| | - Franciane Cabral Pinheiro
- Laboratório de Avaliações Farmacológicas e Toxicológicas Aplicadas às Moléculas Bioativas, LaftamBio Pampa, Universidade Federal do Pampa, Campus Itaqui, Rua Luiz Joaquim de Sá Britto, s/n - Bairro: Promorar, Itaqui, Rio Grande do Sul, CEP 97650-000, Brazil
| | - Elize Aparecida Santos Musachio
- Laboratório de Avaliações Farmacológicas e Toxicológicas Aplicadas às Moléculas Bioativas, LaftamBio Pampa, Universidade Federal do Pampa, Campus Itaqui, Rua Luiz Joaquim de Sá Britto, s/n - Bairro: Promorar, Itaqui, Rio Grande do Sul, CEP 97650-000, Brazil
| | - Luana Barreto Meichtry
- Laboratório de Avaliações Farmacológicas e Toxicológicas Aplicadas às Moléculas Bioativas, LaftamBio Pampa, Universidade Federal do Pampa, Campus Itaqui, Rua Luiz Joaquim de Sá Britto, s/n - Bairro: Promorar, Itaqui, Rio Grande do Sul, CEP 97650-000, Brazil
| | - Manoela do Sacramento
- Laboratório de Síntese Orgânica Limpa, LASOL, Centro de Ciências Químicas, Farmacêuticas e de Alimentos (CCQFA), Universidade Federal de Pelotas, Campus Universitário, S/N - Prédio/Bloco: 30 e 32, Capão do Leão, Rio Grande do Sul, CEP 96160-000, Brazil
| | - Diego Alves
- Laboratório de Síntese Orgânica Limpa, LASOL, Centro de Ciências Químicas, Farmacêuticas e de Alimentos (CCQFA), Universidade Federal de Pelotas, Campus Universitário, S/N - Prédio/Bloco: 30 e 32, Capão do Leão, Rio Grande do Sul, CEP 96160-000, Brazil
| | - Diogo La Rosa Novo
- Centro de Ciências Químicas, Farmacêuticas e de Alimentos, Universidade Federal de Pelotas, Campus Universitário, S/N - Prédio/Bloco: 30 e 32, Capão do Leão, Rio Grande do Sul, CEP 96160-000, Brazil
| | - Márcia Foster Mesko
- Centro de Ciências Químicas, Farmacêuticas e de Alimentos, Universidade Federal de Pelotas, Campus Universitário, S/N - Prédio/Bloco: 30 e 32, Capão do Leão, Rio Grande do Sul, CEP 96160-000, Brazil
| | - Marina Prigol
- Laboratório de Avaliações Farmacológicas e Toxicológicas Aplicadas às Moléculas Bioativas, LaftamBio Pampa, Universidade Federal do Pampa, Campus Itaqui, Rua Luiz Joaquim de Sá Britto, s/n - Bairro: Promorar, Itaqui, Rio Grande do Sul, CEP 97650-000, Brazil; Department of Nutrition, Universidade Federal do Pampa, Campus Itaqui, Rua Luiz Joaquim de Sá Britto, s/n - Bairro: Promorar, Itaqui, Rio Grande do Sul, CEP 97650-000, Brazil.
| |
Collapse
|
15
|
Sidorova YA, Volcho KP, Salakhutdinov NF. Neuroregeneration in Parkinson's Disease: From Proteins to Small Molecules. Curr Neuropharmacol 2019; 17:268-287. [PMID: 30182859 PMCID: PMC6425072 DOI: 10.2174/1570159x16666180905094123] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2018] [Revised: 08/16/2018] [Accepted: 08/30/2018] [Indexed: 01/07/2023] Open
Abstract
Background: Parkinson’s disease (PD) is the second most common neurodegenerative disorder worldwide, the lifetime risk of developing this disease is 1.5%. Motor diagnostic symptoms of PD are caused by degeneration of nigrostria-tal dopamine neurons. There is no cure for PD and current therapy is limited to supportive care that partially alleviates dis-ease signs and symptoms. As diagnostic symptoms of PD result from progressive degeneration of dopamine neurons, drugs restoring these neurons may significantly improve treatment of PD. Method: A literature search was performed using the PubMed, Web of Science and Scopus databases to discuss the pro-gress achieved in the development of neuroregenerative agents for PD. Papers published before early 2018 were taken into account. Results: Here, we review several groups of potential agents capable of protecting and restoring dopamine neurons in cul-tures or animal models of PD including neurotrophic factors and small molecular weight compounds. Conclusion: Despite the promising results of in vitro and in vivo experiments, none of the found agents have yet shown conclusive neurorestorative properties in PD patients. Meanwhile, a few promising biologicals and small molecules have been identified. Their further clinical development can eventually give rise to disease-modifying drugs for PD. Thus, inten-sive research in the field is justified.
Collapse
Affiliation(s)
- Yulia A Sidorova
- Laboratory of Molecular Neuroscience, Institute of Biotechnology, University of Helsinki, Helsinki, Finland
| | - Konstantin P Volcho
- Novosibirsk Institute of Organic Chemistry, Novosibirsk, Russian Federation.,Novosibirsk State University, Novosibirsk, Russian Federation
| | - Nariman F Salakhutdinov
- Novosibirsk Institute of Organic Chemistry, Novosibirsk, Russian Federation.,Novosibirsk State University, Novosibirsk, Russian Federation
| |
Collapse
|
16
|
Nanodelivery of cerebrolysin reduces pathophysiology of Parkinson's disease. PROGRESS IN BRAIN RESEARCH 2019; 245:201-246. [DOI: 10.1016/bs.pbr.2019.03.014] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
|
17
|
Quispe RL, Jaramillo ML, Galant LS, Engel D, Dafre AL, Teixeira da Rocha JB, Radi R, Farina M, de Bem AF. Diphenyl diselenide protects neuronal cells against oxidative stress and mitochondrial dysfunction: Involvement of the glutathione-dependent antioxidant system. Redox Biol 2019; 20:118-129. [PMID: 30308475 PMCID: PMC6176650 DOI: 10.1016/j.redox.2018.09.014] [Citation(s) in RCA: 35] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2018] [Revised: 09/18/2018] [Accepted: 09/24/2018] [Indexed: 12/23/2022] Open
Abstract
Oxidative stress and mitochondrial dysfunction are critical events in neurodegenerative diseases; therefore, molecules that increase cellular antioxidant defenses represent a future pharmacologic strategy to counteract such conditions. The aim of this study was to investigate the potential protective effect of (PhSe)2 on mouse hippocampal cell line (HT22) exposed to tert-BuOOH (in vitro model of oxidative stress), as well as to elucidate potential mechanisms underlying this protection. Our results showed that tert-BuOOH caused time- and concentration-dependent cytotoxicity, which was preceded by increased oxidants production and mitochondrial dysfunction. (PhSe)2 pre-incubation significantly prevented these cytotoxic events and the observed protective effects were paralleled by the upregulation of the cellular glutathione-dependent antioxidant system: (PhSe)2 increased GSH levels (> 60%), GPx activity (6.9-fold) and the mRNA expression of antioxidant enzymes Gpx1 (3.9-fold) and Gclc (2.3-fold). Of note, the cytoprotective effect of (PhSe)2 was significantly decreased when cells were treated with mercaptosuccinic acid, an inhibitor of GPx, indicating the involvement of GPx modulation in the observed protective effect. In summary, the present findings bring out a new action mechanism concerning the antioxidant properties of (PhSe)2. The observed upregulation of the glutathione-dependent antioxidant system represents a future pharmacologic possibility that goes beyond the well-known thiol-peroxidase activity of this compound.
Collapse
Affiliation(s)
- Ruth Liliám Quispe
- Neuroscience PhD Program, Department of Biochemistry, Federal University of Santa Catarina, Florianópolis, SC, Brazil
| | - Michael Lorenz Jaramillo
- Department of Cell Biology, Embryology and Genetics, Federal University of Santa Catarina, SC, Brazil
| | - Leticia Selinger Galant
- Biochemistry PhD Program, Department of Biochemistry, Federal University of Santa Catarina, Florianópolis, SC, Brazil
| | - Daiane Engel
- Neuroscience PhD Program, Department of Biochemistry, Federal University of Santa Catarina, Florianópolis, SC, Brazil
| | - Alcir Luiz Dafre
- Neuroscience PhD Program, Department of Biochemistry, Federal University of Santa Catarina, Florianópolis, SC, Brazil
| | | | - Rafael Radi
- Department of Biochemistry and Center for Free Radical and Biomedical Research (CEINBIO), Facultad de Medicina, Universidad de la República, Montevideo, Uruguay
| | - Marcelo Farina
- Neuroscience PhD Program, Department of Biochemistry, Federal University of Santa Catarina, Florianópolis, SC, Brazil.
| | - Andreza Fabro de Bem
- Neuroscience PhD Program, Department of Biochemistry, Federal University of Santa Catarina, Florianópolis, SC, Brazil; Department of Physiological Sciences, Institute of Biological Sciences, University of Brasília, Brasília, Brazil.
| |
Collapse
|
18
|
Actions of Brain-Derived Neurotrophin Factor in the Neurogenesis and Neuronal Function, and Its Involvement in the Pathophysiology of Brain Diseases. Int J Mol Sci 2018; 19:ijms19113650. [PMID: 30463271 PMCID: PMC6274766 DOI: 10.3390/ijms19113650] [Citation(s) in RCA: 175] [Impact Index Per Article: 29.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2018] [Revised: 11/13/2018] [Accepted: 11/15/2018] [Indexed: 12/12/2022] Open
Abstract
It is well known that brain-derived neurotrophic factor, BDNF, has an important role in a variety of neuronal aspects, such as differentiation, maturation, and synaptic function in the central nervous system (CNS). BDNF stimulates mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK), phosphoinositide-3kinase (PI3K), and phospholipase C (PLC)-gamma pathways via activation of tropomyosin receptor kinase B (TrkB), a high affinity receptor for BDNF. Evidence has shown significant contributions of these signaling pathways in neurogenesis and synaptic plasticity in in vivo and in vitro experiments. Importantly, it has been demonstrated that dysfunction of the BDNF/TrkB system is involved in the onset of brain diseases, including neurodegenerative and psychiatric disorders. In this review, we discuss actions of BDNF and related signaling molecules on CNS neurons, and their contributions to the pathophysiology of brain diseases.
Collapse
|
19
|
Neuroprotective effect of 1-Deoxynojirimycin on cognitive impairment, β-amyloid deposition, and neuroinflammation in the SAMP8 mice. Biomed Pharmacother 2018; 106:92-97. [DOI: 10.1016/j.biopha.2018.06.106] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2018] [Revised: 06/18/2018] [Accepted: 06/18/2018] [Indexed: 01/28/2023] Open
|
20
|
Sex-specific differences in corticosterone secretion, behavioral phenotypes and expression of TrkB.T1 and TrkB.FL receptor isoforms: Impact of systemic TrkB inhibition and combinatory stress exposure in adolescence. Prog Neuropsychopharmacol Biol Psychiatry 2018; 86:10-23. [PMID: 29753050 DOI: 10.1016/j.pnpbp.2018.05.002] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/25/2017] [Revised: 04/04/2018] [Accepted: 05/08/2018] [Indexed: 12/12/2022]
Abstract
Stress exposure has been implicated in the development of mood disorders, although little is known about the lasting effects of repeated stress during the adolescent period on sex-specific differences in endocrine and plasticity-signaling responses in adulthood. Using a 10-day combinatory stress paradigm (postnatal day (PND) 26 to 35), we examined sex-specific impact of adolescent stress and inhibition of tyrosine-related kinase B (TrkB) receptor (ANA-12; 0.5 mg/kg, i.p.) on 1) adolescent blood corticosterone levels, 2) adult locomotion and anxiety-like behavior, and 3) region-specific differences in endogenous TrkB full-length (TrkB.FL) and truncated (TrkB.T1) receptor isoforms. Blood collected on days 1, 5 and 10 revealed elevated basal and stress-induced CORT secretion in females compared to males, while ANA-12 attenuated CORT elevations post stress in both sexes. As adults, all females exhibited higher locomotor and exploratory activity than males in the open field test and elevated plus maze, and differences were comparable in the forced swim within stress-naïve and stress groups. Biochemically, vehicle-treated males showed elevated TrkB.T1 and TrkB.FL compared to vehicle-treated females in the PFC, hippocampus and NAc, and levels were consistently attenuated by ANA-12 treatment in non-stress males. With regards to stress exposure, expression of both isoforms was strongly down-regulated in the NAc of males only and was associated with increased TrkB.T1 in the PFC. ANA-12 enhanced expression in females, independent of stress exposure, compared to vehicle-treated counterparts, expression being increased for TrkB.T1 versus TrkB.FL and magnitude of the changes being region-specific. In contrast, ANA-12 effects in stressed males were restricted to inhibition of both isoforms in the hippocampus. Together, our findings support that TrkB activation, contingent on stress exposure, differentially affects TrkB isoform regulation during adulthood. Sex-specific biochemical responses at delayed intervals following adolescent stress exposure further support the need to include the sex variable in animal models.
Collapse
|
21
|
Perin G, Santoni P, Barcellos AM, Nobre PC, Jacob RG, Lenardão EJ, Santi C. Selenomethoxylation of Alkenes Promoted by Oxone®. European J Org Chem 2018. [DOI: 10.1002/ejoc.201701775] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Affiliation(s)
- Gelson Perin
- Laboratório de Síntese Orgânica Limpa - LASOL; Federal University of Pelotas - UFPel; P.O. Box 354 96010-900 Pelotas - RS Brazil
| | - Paolo Santoni
- Department of Pharmaceutical Sciences; University of Perugia; Via del Liceo 1 Perugia (PG) Italy
| | - Angelita M. Barcellos
- Laboratório de Síntese Orgânica Limpa - LASOL; Federal University of Pelotas - UFPel; P.O. Box 354 96010-900 Pelotas - RS Brazil
| | - Patrick C. Nobre
- Laboratório de Síntese Orgânica Limpa - LASOL; Federal University of Pelotas - UFPel; P.O. Box 354 96010-900 Pelotas - RS Brazil
| | - Raquel G. Jacob
- Laboratório de Síntese Orgânica Limpa - LASOL; Federal University of Pelotas - UFPel; P.O. Box 354 96010-900 Pelotas - RS Brazil
| | - Eder J. Lenardão
- Laboratório de Síntese Orgânica Limpa - LASOL; Federal University of Pelotas - UFPel; P.O. Box 354 96010-900 Pelotas - RS Brazil
| | - Claudio Santi
- Department of Pharmaceutical Sciences; University of Perugia; Via del Liceo 1 Perugia (PG) Italy
| |
Collapse
|
22
|
Goes AT, Jesse CR, Antunes MS, Lobo Ladd FV, Lobo Ladd AA, Luchese C, Paroul N, Boeira SP. Protective role of chrysin on 6-hydroxydopamine-induced neurodegeneration a mouse model of Parkinson's disease: Involvement of neuroinflammation and neurotrophins. Chem Biol Interact 2018; 279:111-120. [DOI: 10.1016/j.cbi.2017.10.019] [Citation(s) in RCA: 61] [Impact Index Per Article: 10.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2017] [Revised: 07/15/2017] [Accepted: 10/16/2017] [Indexed: 01/28/2023]
|
23
|
Na ES, De Jesús-Cortés H, Martinez-Rivera A, Kabir ZD, Wang J, Ramesh V, Onder Y, Rajadhyaksha AM, Monteggia LM, Pieper AA. D-cycloserine improves synaptic transmission in an animal model of Rett syndrome. PLoS One 2017; 12:e0183026. [PMID: 28813484 PMCID: PMC5559075 DOI: 10.1371/journal.pone.0183026] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2017] [Accepted: 07/30/2017] [Indexed: 01/24/2023] Open
Abstract
Rett syndrome (RTT), a leading cause of intellectual disability in girls, is predominantly caused by mutations in the X-linked gene MECP2. Disruption of Mecp2 in mice recapitulates major features of RTT, including neurobehavioral abnormalities, which can be reversed by re-expression of normal Mecp2. Thus, there is reason to believe that RTT could be amenable to therapeutic intervention throughout the lifespan of patients after the onset of symptoms. A common feature underlying neuropsychiatric disorders, including RTT, is altered synaptic function in the brain. Here, we show that Mecp2tm1.1Jae/y mice display lower presynaptic function as assessed by paired pulse ratio, as well as decreased long term potentiation (LTP) at hippocampal Schaffer–collateral-CA1 synapses. Treatment of Mecp2tm1.1Jae/y mice with D-cycloserine (DCS), an FDA-approved analog of the amino acid D-alanine with antibiotic and glycinergic activity, corrected the presynaptic but not LTP deficit without affecting deficient hippocampal BDNF levels. DCS treatment did, however, partially restore lower BDNF levels in the brain stem and striatum. Thus, treatment with DCS may mitigate the severity of some of the neurobehavioral symptoms experienced by patients with Rett syndrome.
Collapse
Affiliation(s)
- Elisa S. Na
- Department of Psychology & Philosophy, Texas Woman’s University, Denton, TX, United States of America
| | - Héctor De Jesús-Cortés
- Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA, United States of America
| | - Arlene Martinez-Rivera
- Division of Pediatric Neurology, Department of Pediatrics, Weill Cornell Medicine, Cornell University, New York, NY, United States of America
- Weill Cornell Autism Research Program, Weill Cornell Medicine, Cornell University, New York, NY, United States of America
| | - Zeeba D. Kabir
- Division of Pediatric Neurology, Department of Pediatrics, Weill Cornell Medicine, Cornell University, New York, NY, United States of America
- Weill Cornell Autism Research Program, Weill Cornell Medicine, Cornell University, New York, NY, United States of America
| | - Jieqi Wang
- Department of Psychiatry, University of Iowa Carver College of Medicine, Iowa City, IA, United States of America
| | - Vijayashree Ramesh
- Department of Neuroscience, UT Southwestern Medical Center, Dallas, TX, United States of America
| | - Yasemin Onder
- Department of Neuroscience, UT Southwestern Medical Center, Dallas, TX, United States of America
| | - Anjali M. Rajadhyaksha
- Division of Pediatric Neurology, Department of Pediatrics, Weill Cornell Medicine, Cornell University, New York, NY, United States of America
- Weill Cornell Autism Research Program, Weill Cornell Medicine, Cornell University, New York, NY, United States of America
- Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, Cornell University, New York, NY, United States of America
- * E-mail: (AMR); (LMM); (AAP)
| | - Lisa M. Monteggia
- Department of Neuroscience, UT Southwestern Medical Center, Dallas, TX, United States of America
- * E-mail: (AMR); (LMM); (AAP)
| | - Andrew A. Pieper
- Weill Cornell Autism Research Program, Weill Cornell Medicine, Cornell University, New York, NY, United States of America
- Department of Psychiatry, University of Iowa Carver College of Medicine, Iowa City, IA, United States of America
- Department of Neurology, University of Iowa Carver College of Medicine, Iowa City, IA, United States of America
- Department of Free Radical and Radiation Biology, University of Iowa Carver College of Medicine, Iowa City, IA, United States of America
- Department of Veterans Affairs, University of Iowa Carver College of Medicine, Iowa City, IA, United States of America
- Pappajohn Biomedical Institute, University of Iowa Carver College of Medicine, Iowa City, IA, United States of America
- * E-mail: (AMR); (LMM); (AAP)
| |
Collapse
|
24
|
Antipova VA, Holzmann C, Schmitt O, Wree A, Hawlitschka A. Botulinum Neurotoxin A Injected Ipsilaterally or Contralaterally into the Striatum in the Rat 6-OHDA Model of Unilateral Parkinson's Disease Differently Affects Behavior. Front Behav Neurosci 2017; 11:119. [PMID: 28680396 PMCID: PMC5478737 DOI: 10.3389/fnbeh.2017.00119] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2017] [Accepted: 06/06/2017] [Indexed: 12/30/2022] Open
Abstract
Parkinson's disease (PD) is one of the most frequent neurodegenerative disorders. The loss of dopaminergic neurons in the substantia nigra leads to a disinhibition of cholinergic interneurons in the striatum. Pharmacotherapeutical strategies of PD-related hypercholinism have numerous adverse side effects. We previously showed that ipsilateral intrastriatal injections of 1 ng in unilaterally 6-hydroxydopamine (6-OHDA)-lesioned rats inhibit apomorphine-induced rotation behavior significantly up to 6 months. In this study, we extended the behavioral testing of ipsilateral botulinum neurotoxin A (BoNT-A)-injection and additionally investigated the impact of intrastriatal BoNT-A-injections contralateral to the 6-OHDA-lesioned hemisphere on the basal ganglia circuity and motor functions. We hypothesized that the interhemispheric differences of acetylcholine (ACh) concentration seen in unilateral hemi-PD should be differentially and temporally influenced by the ipsilateral or contralateral injection of BoNT-A. Hemi-PD rats were injected with 1 ng BoNT-A or vehicle substance into either the ipsilateral or contralateral striatum 6 weeks after 6-OHDA-lesion and various behaviors were tested. In hemi-PD rats intrastriatal ipsilateral BoNT-A-injections significantly reduced apomorphine-induced rotations and increased amphetamine-induced rotations, but showed no significant improvement of forelimb usage and akinesia, lateralized sensorimotor integration and also no effect on spontaneous locomotor activity. However, intrastriatal BoNT-A-injections contralateral to the lesion led to a significant increase of the apomorphine-induced turning rate only 2 weeks after the treatment. The apomorphine-induced rotation rate decreases thereafter to a value below the initial rotation rate. Amphetamine-induced rotations were not significantly changed after BoNT-A-application in comparison to sham-treated animals. Forelimb usage was temporally improved by contralateral BoNT-A-injection at 2 weeks after BoNT-A. Akinesia and lateralized sensorimotor integration were also improved, but contralateral BoNT-A-injection had no significant effect on spontaneous locomotor activity. These long-ranging and different effects suggest that intrastriatally applied BoNT-A acts not only as an inhibitor of ACh release but also has long-lasting impact on transmitter expression and thereby on the basal ganglia circuitry. Evaluation of changes of transmitter receptors is subject of ongoing studies of our group.
Collapse
Affiliation(s)
- Veronica A. Antipova
- Institute of Anatomy, Rostock University Medical CenterRostock, Germany
- Institute of Macroscopic and Clinical Anatomy, Medical University of GrazGraz, Austria
| | - Carsten Holzmann
- Institute of Medical Genetics, Rostock University Medical CenterRostock, Germany
| | - Oliver Schmitt
- Institute of Anatomy, Rostock University Medical CenterRostock, Germany
| | - Andreas Wree
- Institute of Anatomy, Rostock University Medical CenterRostock, Germany
| | | |
Collapse
|
25
|
Guo XX, He QZ, Li W, Long DX, Pan XY, Chen C, Zeng HC. Brain-Derived Neurotrophic Factor Mediated Perfluorooctane Sulfonate Induced-Neurotoxicity via Epigenetics Regulation in SK-N-SH Cells. Int J Mol Sci 2017; 18:ijms18040893. [PMID: 28441774 PMCID: PMC5412472 DOI: 10.3390/ijms18040893] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2017] [Revised: 04/17/2017] [Accepted: 04/19/2017] [Indexed: 12/12/2022] Open
Abstract
Perfluorooctane sulfonate (PFOS), a new kind of persistent organic pollutant, is widely distributed in the environment and exists in various organisms, where it is also a neurotoxic compound. However, the potential mechanism of its neurotoxicity is still unclear. To examine the role of epigenetics in the neurotoxicity induced by PFOS, SK-N-SH cells were treated with different concentrations of PFOS or control medium (0.1% DMSO) for 48 h. The mRNA levels of DNA methyltransferases (DNMTs) and Brain-derived neurotrophic factor (BDNF), microRNA-16, microRNA-22, and microRNA-30a-5p were detected by Quantitative PCR (QPCR). Enzyme Linked Immunosorbent Assay (ELISA) was used to measure the protein levels of BDNF, and a western blot was applied to analyze the protein levels of DNMTs. Bisulfite sequencing PCR (BSP) was used to detect the methylation status of the BDNF promoter I and IV. Results of MTT assays indicated that treatment with PFOS could lead to a significant decrease of cell viability, and the treated cells became shrunk. In addition, PFOS exposure decreased the expression of BDNF at mRNA and protein levels, increased the expression of microRNA-16, microRNA-22, microRNA-30a-5p, and decreased the expression of DNMT1 at mRNA and protein levels, but increased the expression of DNMT3b at mRNA and protein levels. Our results also demonstrate that PFOS exposure changes the methylation status of BDNF promoter I and IV. The findings of the present study suggest that methylation regulation of BDNF gene promoter and increases of BDNF-related-microRNA might underlie the mechanisms of PFOS-induced neurotoxicity.
Collapse
Affiliation(s)
- Xin-Xin Guo
- Department of Preventive Medicine, School of Public Health, University of South China, Hengyang 421001, China.
| | - Qing-Zhi He
- School of Pharmacy and Biology, University of South China, Hengyang 421001, China.
- Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, Hengyang 421001, China.
| | - Wu Li
- Department of Preventive Medicine, School of Public Health, University of South China, Hengyang 421001, China.
| | - Ding-Xin Long
- Department of Preventive Medicine, School of Public Health, University of South China, Hengyang 421001, China.
| | - Xiao-Yuan Pan
- Department of Preventive Medicine, School of Public Health, University of South China, Hengyang 421001, China.
| | - Cong Chen
- Department of Preventive Medicine, School of Public Health, University of South China, Hengyang 421001, China.
| | - Huai-Cai Zeng
- Department of Preventive Medicine, School of Public Health, University of South China, Hengyang 421001, China.
- Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, Hengyang 421001, China.
| |
Collapse
|
26
|
Sampaio TB, Savall AS, Gutierrez MEZ, Pinton S. Neurotrophic factors in Alzheimer's and Parkinson's diseases: implications for pathogenesis and therapy. Neural Regen Res 2017; 12:549-557. [PMID: 28553325 PMCID: PMC5436343 DOI: 10.4103/1673-5374.205084] [Citation(s) in RCA: 135] [Impact Index Per Article: 19.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
Neurotrophic factors comprise essential secreted proteins that have several functions in neural and non-neural tissues, mediating the development, survival and maintenance of peripheral and central nervous system. Therefore, neurotrophic factor issue has been extensively investigated into the context of neurodegenerative diseases. Alzheimer's disease and Parkinson's disease show changes in the regulation of specific neurotrophic factors and their receptors, which appear to be critical for neuronal degeneration. Indeed, neurotrophic factors prevent cell death in degenerative processes and can enhance the growth and function of affected neurons in these disorders. Based on recent reports, this review discusses the main findings related to the neurotrophic factor support – mainly brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor – in the survival, proliferation and maturation of affected neurons in Alzheimer's disease and Parkinson's disease as well as their putative application as new therapeutic approach for these diseases management.
Collapse
Affiliation(s)
- Tuane Bazanella Sampaio
- Departamento de Farmacologia, Centro de Ciências Biológicas, Universidade Federal de Santa Catarina, Florianópolis, SC, Brazil.,Universidade Federal do Pampa - Campus Uruguaiana, Uruguaiana, RS, Brazil
| | - Anne Suely Savall
- Universidade Federal do Pampa - Campus Uruguaiana, Uruguaiana, RS, Brazil
| | | | - Simone Pinton
- Universidade Federal do Pampa - Campus Uruguaiana, Uruguaiana, RS, Brazil
| |
Collapse
|